Safety and efficacy of remimazolam combined with nalbuphine for patients in enhanced recovery after painless hysteroscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200057416

Enrollment

Unknown

Registered

2022-03-11

Start date

2022-04-06

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intravenous anesthesia in hysteroscopic examination or operation

Interventions

Group P( propofol group):propofol

Group R1:remimazolam

Group R2:remimazolam

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients selected for painless hysteroscopy, ASAI-II; 2. 18-60 years old; 3. BMI 18-30 kg/m2 4. Normal communication; 5. Volunteer and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe respiratory and circulatory diseases: such as severe coronary heart disease, chronic obstructive pulmonary disease, etc; 2. Endocrine system diseases: such as pituitary adenoma, severe diabetes, hypercortisolism, pheochromocytoma, etc; 3. Psychopsychological diseases: such as schizophrenics, depression, chronic analgesics, alcoholism, opioid addicts; 4. Allergy history of narcotic drugs used.

Design outcomes

Primary

Measure	Time frame
Onset time;Duration time given initial dose;time to Ramsay 5;Duration of procedure;Recovery time;Orientation recovery time;hemodynamic parameters;Ramsay sedative score;	—

Secondary

Measure	Time frame
BPS-NI;	—

Contacts

Public ContactLiu Xuesheng

Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University

liuxuesheng@ahmu.edu.cn+86 18655193385

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026